Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04071223 · ClinicalTrials.gov registry record · Phase 2

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

A Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v8, sponsored by National Cancer Institute (NCI).

Active
Registry status
Phase 2
Development phase
134
Enrollment target
20
Study locations

NCT04071223 is a Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v8 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 134 participants, below the 200-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04071223, a Phase 2 study of Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer AJCC v8, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
134 participants
Enrollment target
20
Study locations

Study Summary

This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to normal cells. Cabozantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving radium-223 dichloride and cabozantinib may help lessen the pain and symptoms from renal cell cancer that has spread to the bone, compared to cabozantinib alone.

Conditions Studied

Clear Cell Renal Cell Carcinoma Stage IV Renal Cell Cancer AJCC v8 Metastatic Malignant Neoplasm in the Bone Advanced Renal Cell Carcinoma Chromophobe Renal Cell Carcinoma Papillary Renal Cell Carcinoma Unclassified Renal Cell Carcinoma Kidney Medullary Carcinoma Collecting Duct Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Bone Scan
  • DRUG Cabozantinib S-malate
  • PROCEDURE Computed Tomography
  • PROCEDURE Magnetic Resonance Imaging

Study Locations (20)

Illinois

  • Rush MD Anderson Cancer Center - Chicago
  • University of Chicago Comprehensive Cancer Center - Chicago
  • Cancer Care Specialists of Illinois - Decatur - Decatur
  • Loyola University Medical Center - Maywood
  • UC Comprehensive Cancer Center at Silver Cross - New Lenox
  • Rush MD Anderson Cancer Center at Rush Oak Park - Oak Park
  • University of Chicago Medicine-Orland Park - Orland Park

Iowa

  • UI Health Care Mission Cancer and Blood - Ankeny Clinic - Ankeny
  • Iowa Methodist Medical Center - Des Moines
  • UI Health Care Mission Cancer and Blood - Des Moines Clinic - Des Moines
  • University of Iowa/Holden Comprehensive Cancer Center - Iowa City

Kansas

  • University of Kansas Cancer Center - Kansas City
  • University of Kansas Cancer Center-Overland Park - Overland Park
  • University of Kansas Hospital-Westwood Cancer Center - Westwood

Louisiana

  • East Jefferson General Hospital - Metairie
  • LSU Healthcare Network / Metairie Multi-Specialty Clinic - Metairie
  • Tulane University School of Medicine - New Orleans

California

  • UC San Diego Moores Cancer Center - La Jolla
  • University of California Davis Comprehensive Cancer Center - Sacramento

Alabama

  • University of Alabama at Birmingham Cancer Center - Birmingham

Trial Details

FieldValue
Enrollment Target 134 participants
Start Date 2020-07-29
Est. Completion 2026-10-01
Phase Phase 2

Sponsor

National Cancer Institute (NCI)

3,257 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04071223

The ClinicalTrials.gov registry entry for NCT04071223 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 200-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (33% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT04071223 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Illinois, Iowa, Kansas.

Frequently Asked Questions

What is clinical trial NCT04071223 about?

NCT04071223 is a clinical study titled "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study". This phase II trial studies whether adding radium-223 dichloride to the usual treatment, cabozantinib, improves outcomes in patients with renal cell cancer that has spread to the bone. Radioactive drugs such as radium-223 dichloride may directly target radiation to cancer cells and minimize harm to ...

What is the current status of trial NCT04071223?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 134 participants. The study started on 2020-07-29. Estimated completion is 2026-10-01.

What conditions does trial NCT04071223 study?

This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8, Metastatic Malignant Neoplasm in the Bone, Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma.

What interventions are being tested in trial NCT04071223?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Scan (PROCEDURE), Cabozantinib S-malate (DRUG), Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE).

Who is sponsoring clinical trial NCT04071223?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04071223 being conducted?

This trial has 20 study locations across Alabama, California, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Clear Cell Renal Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Clear Cell Renal Cell Carcinoma

All registered trials for this condition

Stage IV Renal Cell Cancer AJCC v8

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.